Site is Being Upgraded

Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine and L-Arginine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 25/February/2018, 10.26 pm

Activation of the PD-1 pathway for Pain therapy: Venlafaxine (brand name: effexor), an antidepressant which functions as a selective serotonin-norepinephrine reuptake inhibitor, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 25/February/2017, 10.16 pm
February 25, 2018
Natural product-based therapy for Non-alcoholic fatty liver disease (NAFLD):  Syringic acid promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/February/2018, 10.36 pm
February 25, 2018
Show all

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine and L-Arginine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene


From the Significance of the study to Public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to therapeutic opportunity:  

This study suggests, for the first time, that  a therapeutic mix encompassing Pyridoxamine and L-Arginine, by increasing the expression of its target gene, it may increase the expression of oncoprotein BMI-1 and suppress the expression of tumor suppressor  and the ageing marker INK4a/p16 (figure 1 ).

[easy_payment currency=”USD”]

Figure 1. Mechanistic insight into how a therapeutic mix encompassing Pyridoxamine and L-Arginine may function as a cardioprotective agent. A therapeutic mix encompassing Pyridoxamine and L-Arginine inhibits dilated cardiomyopathy and heart failure via down regulation of ageing/senescence marker INK4a

Figure 2. The chemical structures of Pyridoxamine and L-Arginine


Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility.

Thus, (1) by treating myocardial patients with Pyridoxamine and L-Arginine, one may prevent Dilated  cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) pharmacological formulations encompassing Pyridoxamine and L-Arginine  or their analogues, either alone or in combination with any of the known drugs that are used to treat cardiomyopathy” may be used to inhibit dilated cardiomyopathy and heart failure (figure 1).

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How a therapeutic mix encompassing Pyridoxamine and L-Arginine increases the expression of oncoprotein BMI-1, while decreasing the expression of INK4a

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine and L-Arginine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 25/February/2018, 10.27 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.